Frontiers in Immunology
Cure8 research brief
Why This Matters
Spatially resolved profiling could identify the specific cell neighborhoods and signaling circuits that drive disease in a person’s gut tissue, which may help predict who will respond to particular biologics or small molecules and enable more precise clinical trials.
For now, this work is mainly relevant to research and early translational efforts rather than immediate treatment choices for patients.
Who Should Pay Attention
Researchers studying IBD pathogenesis, translational scientists developing biomarkers or precision trials, clinicians involved in IBD clinical research, and patients interested in how future precision therapies may be developed.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This Frontiers in Immunology review argues for viewing IBD as spatially structured mucosal immune niches and discusses how single-cell atlases and spatial multi-omics could guide target discovery, pharmacodynamic endpoints, biomarker development, and biomarker-enriched trial design.
It uses example pathways (TNF, IL-23, OSM, TL1A, integrins, JAK–STAT, S1P) and emphasizes that spatial biomarkers are mostly at discovery/early translational stages and require standardization and validation. The article is a conceptual and methodological review (structured abstract provided by the journal).
It does not present new trial results but outlines a staged translational path from tissue atlases to adaptive precision trials and highlights practical needs (sampling standards, harmonized computation, longitudinal and multicenter validation).
Practical takeaway: spatial multi-omics can generate hypotheses and help design enriched clinical trials and pharmacodynamic readouts, but it is not yet ready to guide routine treatment selection.
Keep In Mind
This is a review/position paper (abstract-level content) that synthesizes existing single-cell and spatial multi-omics work and proposes translational pathways.
It does not report new clinical trial outcomes; most spatial biomarkers discussed are at discovery or early translational stages and need standardized sampling, computational harmonization, longitudinal data, and multicenter validation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Immunology
PublisherFrontiers Media SA
AuthorsHai Wang, Xiaolong Zhao, Jie Yang
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 18, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Neglected kingdoms: the gut virome, mycobiome and their role in inflammatory bowel disease.
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these...
Crosstalk between circRNAs and the classic signaling pathways in IBD.
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
From signals to systems: the epigenetic-microbiome-mitochondrial axis in IBD pathogenesis.
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...